Chordate Medical

Two of Chordate Medical’s ten largest shareholders have informed the company of their intention to subscribe for Units in the ongoing rights issue.

Hawoc Investment AB had previously committed to a subscription of SEK 500,000. In addition to this, Hawoc has now informed the company that they intend to subscribe to their full pro rata right in the ongoing issue, amounting to a total of SEK 2,122,000, including the original commitment. Hawoc Investment AB is the company's second-largest shareholder.

Furthermore, David Nyman has informed the company of his intention to subscribe to his pro rata right, equivalent to SEK 528,000.

"It is highly gratifying to receive this strong support for the company and the rights issue from our major shareholders. The confirmation of continued support and confidence in our strategic plan from so many of our principal owners is of crucial importance to the company," says Anders Weilandt, CEO of Chordate.

This means that a number of existing shareholders in Chordate Medical have now collectively entered into subscription commitments and declarations of intent for a total amount of circa 9.9 MSEK, which corresponds to circa 44.6 percent of the issue.